Abstract Library

#4387 Exenatide-test for diagnosing endogenous hyperinsulinemic hypoglycaemia: A randomised placebo-controlled cross-over proof-of-principle study – FAST study

Introduction: The gold standard to diagnose endogenous hyperinsulinemic hypoglycaemia (EHH) is the fasting test which is cumbersome and incurs high costs. In the setting of radio-labelled 68Ga-exendin-4 PET/CT in patients with EHH (to localise insulinoma), we unexpectedly observed clinically relevant hypoglycaemia following administration of the tracer, which does usually not occur after GLP-1 agonist therapy in type 2 diabetic patients and in healthy subjects.

Conference:

Presenting Author: Christ E

Authors: Hepprich M, Romberg C, Fricke J, Freitag M, Mudry J,

Keywords: endogenous hyperinsulinemic hypoglycaemia, insulinoma, Exendin, Fasting test,

#1542 Selective Inhibition of PI3Kalpha (BYL719) - Promising Therapeutic Option for Neuroendocrine Tumors?

Introduction: Neuroendocrine tumors are heterogeneous, often functional malignancies and their therapeutic options are limited. As the PI3 kinase signaling is ­in GEP-NENs, selective PI3Kalpha inhibitors may be more potent than panPI3K inhibitors.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Grabowski P

Authors: Nölting S, Rentsch J, Freitag H, Briest F, Schrader J,

Keywords: PI3Kalpha, BYL719, neuroendocrine tumor cell lines,

#1404 The Proteasome Inhibitor Bortezomib Is a Highly Effective Treatment Option for Gastroenteropancreatic Neuroendocrine Neoplasms and Sensitizes to DNA Damaging Therapy In Vitro

Introduction: Gastroenteropancreatic neuroendocrine neoplasms are fairly rare tumors with very heterogeneous behavior and molecular characteristics. Their generally slow proliferation render them virtually resistant to many DNA damaging therapeutic approaches. Bortezomib has been shown to be effective in GEP-NENs in vitro but has been withdrawn from clinical assessment due to a small phase II study on bortezomib monotherapy in 2004.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Briest F

Authors: Briest F, Christen F, Worpenberg L, Welzel M, Freitag H,

Keywords: GEP-NEN, targeted therapy, DNA repair, chemotherapy,

#1172 Dual Inhibition of PI3K and mTORC1/C2 by PKI-587 (PF-05212384) as a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease and Its Effect on AKT-Signaling

Introduction: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) are heterogeneous in their clinical behavior and therapeutic options are still not satisfactory. The “crosstalk” of different signaling pathways in NEN cells appears to be more complex as known already. PKI-587 is a highly potent novel dual inhibitor of PI3K and mTORC1/C2.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Freitag H, Briest F, Christen F, Grass I, Lewens F,

Keywords: dual inhibition, PI3K, mTOR, PKI-587,RAD001, signaling,

#1003 Signalling Pathways in Bronchial Neuroendocrine Tumor Disease and Its Translation to Innovative Targets: The New Kid on the Block

Introduction: Bronchial neuroendocrine neoplasias comprise a wide spectrum of well-differentiated tumors (typical/atypical carcinoids) to undifferentiated carcinomas such as small (SCLC) and large cell (LC) neuroendocrine carcinomas with a fatal prognosis. Therapeutic options are unsatisfactory.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Lewens F

Authors: Lewens F, Freitag H, Briest F, Heilmann M, Schneider C,

Keywords: bronchial, NETs, PI3K, FoxM1, survivin, cell lines, SCLC,